Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study - Concepedia

Concepedia

Publication | Open Access

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

DOI Full Paper Access

15

Citations

22

References

2024

Year

P Clot, Christine Farenc, Benjamin T. Suratt, Tillmann Krahnke, Agnes Tardat, Peter Florian, Robert J. Pomponio, Naimish Patel, Maria Wiekowski, Yong Lin,

Respiratory Research

References

	Year	Citations

Page 1